fulvestrant has been researched along with anastrozole in 115 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.61) | 18.2507 |
| 2000's | 44 (38.26) | 29.6817 |
| 2010's | 56 (48.70) | 24.3611 |
| 2020's | 12 (10.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, JZ; Khan, MZI; Nazli, A; Uzair, M | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Brodie, AM; Grigoryev, DN; Long, BJ; Thiantanawat, A; Tilghman, SL; Yue, W | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Fujita, T; Kaiho, S; Kuwabara, K; Ogata, E; Oizumi, I; Okazaki, T; Tanaka, Y | 1 |
| Mokbel, K | 1 |
| Tominaga, T | 1 |
| Baum, M | 1 |
| Chaudhuri, G; Dinh, H; Mukherjee, TK; Nathan, L | 1 |
| Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A | 1 |
| Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A | 1 |
| Ashby, J; Deghenghi, R; Odum, J; Owens, W | 1 |
| Vergote, I | 1 |
| Howell, A | 1 |
| Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A | 1 |
| Eckhardt, S | 1 |
| Hortobagyi, GN | 1 |
| Baird, A; Bross, PF; Chen, G; Jee, JM; Lostritto, RT; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Williams, G; Williams, GM; Yang, P | 1 |
| Howell, A; Mauriac, L; Osborne, CK | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Tobias, JS | 1 |
| Harwood, KV | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Kaplow, R | 1 |
| Jakesz, R | 1 |
| Bundred, N | 1 |
| Gradishar, WJ; Sahmoud, T | 1 |
| Jones, SE; Pippen, J | 1 |
| Dodwell, D; Vergote, I | 1 |
| Come, SE; Elledge, RM; Howell, A; Jones, SE; Mauriac, L; Osborne, CK; Pippen, J; Robertson, JF; Vergote, I | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Abram, P; Vergote, I | 1 |
| Hoffman, MA; Khan, A | 1 |
| Dodwell, D; Pippen, J | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Brodie, A; Goloubeva, OG; Macedo, LF; Sabnis, GJ | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Aloisi, AM; Ceccarelli, I; Fiorenzani, P; Pessina, F; Sgaragli, G; Valeri, A | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Dewar, J; Ellis, MJ; Feltl, D; Lindemann, J; Llombart-Cussac, A; Macpherson, E; Robertson, JF; Rolski, J | 1 |
| Baumann, CK; Castiglione-Gertsch, M | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| Avellar, MC; Fernandes, SA; Gomes, GR; Lazari, MF; Porto, CS; Siu, ER; Yasuhara, F | 1 |
| Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y | 1 |
| Dowsett, M; Dunbier, A; Ghazoui, Z; Johnston, S; Martin, LA; Pancholi, S; Weigel, MT | 1 |
| Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Di Leo, A; Malorni, L | 1 |
| Campelo, AE; Cutini, PH; Massheimer, VL | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Cunningham, DE; Dacic, S; Keohavong, P; Land, SR; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Gelber, RD; Goldhirsch, A | 1 |
| Dean, A; Dewar, J; Ellis, MJ; Emerson, L; Feltl, D; Lindemann, JP; Llombart-Cussac, A; Robertson, JF; Rolski, J | 1 |
| Channon, E; Dixon, JM; Ellis, IO; Gee, JM; Hyman-Taylor, P; Jahan, A; Nicholson, RI; Robertson, JF; Sibbering, DM | 1 |
| Haaland, B; Lopes, G; Montero, AJ; Tan, PS | 1 |
| Buzdar, AU | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Mehta, A; Tripathy, D | 1 |
| Fan, Y; Gong, DD; Man, CF; Xu, J | 1 |
| Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Bachelot, T; Bonnefoi, H; Breton-Callu, C; Dalenc, F; Daly, C; de Lara, CT; Debled, M; Fournier, M; Gros, A; Iggo, R; Lortal, B; MacGrogan, G; Madranges, N; Mauriac, L; Nikolski, M; Pulido, M; Quenel-Tueux, N; Rabbitts, P; Rudewicz, J; Soueidan, H; Wood, H | 1 |
| Dewar, JA; Ellis, MJ; Feltl, D; Hewson, N; Jasiówka, M; Llombart-Cussac, A; Robertson, JF; Rukazenkov, Y | 1 |
| Creekmore, A; Crowder, R; Doyle, A; Ellis, MJ; Erlichman, C; Gao, F; Guo, Z; Hoog, J; Lockhart, AC; Ma, CX; Naughton, M; Pluard, T; Sanchez, C | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, J; Hayes, DF; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Livingston, RB; Mehta, RS; Rae, JM; Tirumali, NR; Vandenberg, TA | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Alran, S; Balleyguier, C; Becette, V; Bourgier, C; Boussion, V; Cherel, P; Kerbrat, P; Lavau-Denes, S; Lemonnier, J; Lerebours, F; Martin, AL; Mathieu, MC; Mouret-Fourme, E; Mouret-Reynier, MA; Nabholz, JM; Rivera, S; Salmon, R; Sigal, B; Thibault, F; Trassard, M; Venat-Bouvet, L | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Bowers, C; Erickson, D; Takahashi, P; Veldhuis, JD; Yang, R | 1 |
| Niraula, S; Ocana, A | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Bondarenko, IM; Cardona-Huerta, S; Cheung, KL; Dvorkin, M; Ellis, MJ; Fazal, M; Grinsted, LM; Manikhas, A; Noguchi, S; Panasci, L; Philco-Salas, MJ; Robertson, JFR; Rowbottom, J; Ruiz-Borrego, M; Shao, Z; Shparyk, Y; Stuart, M; Trishkina, E | 1 |
| Goodwin, A; Lee, CI; Wilcken, N | 1 |
| Ding, H; Fang, L; Huang, P; Tong, Y; Xin, W; Zhou, Q | 1 |
| Austin, ED; Brittain, EL; Chen, X; Farber-Eger, EH; Fessel, JP; Hemnes, AR; Loyd, JE; Talati, M; West, J | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J | 1 |
| Cheung, KL; Degboe, A; Ellis, MJ; Fazal, M; Lichfield, J; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J | 1 |
| Telford, C | 1 |
| Ellis, MJ; Shafaee, MN | 1 |
| Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J | 1 |
| Baulande, S; Becette, V; Benoist, C; Boulai, A; Bouvet, LV; Briaux, A; Callens, C; Chemlali, W; De La Motte Rouge, T; Lemonnier, J; Lerebours, F; Liang, X; Mouret-Reynier, MA; Rivera, S; Schnitzler, A | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Burki, TK | 1 |
| Sidaway, P | 1 |
| Bradbury, I; Campbell, C; Di Leo, A; Ellis, M; Jiang, Z; Ohno, S; Pritchard, KI; Robertson, JFR | 1 |
| Alba, E; Álvarez, I; Antolín, S; Antón, A; Baena-Cañada, JM; Bermejo, B; Carrasco, E; Chacón, JI; Cirauqui, B; Cruz, J; Del Barco, S; Escudero, MJ; Guerrero-Zotano, A; Martín, M; Martínez-Jáñez, N; Muñoz, M; Ramos, M; Rodríguez-Lescure, Á; Ruiz, V; Ruíz-Borrego, M; Sevillano, E | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Bai, L; Huang, J; Li, Q; Liao, W; Wen, F; Wu, Q; Zhang, N; Zhou, K | 1 |
| Alberini, JL; Becette, V; Boughdad, S; Champion, L; Cherel, P; Fourme, E; Lemonnier, J; Lerebours, F | 1 |
| Duan, S; He, Y; Li, M; Liao, C; Wei, Y; Xiong, Y; Yi, F; Zhang, W | 1 |
| Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S | 1 |
| Huang, P; Huang, X; Lin, S; Liu, Y; Luo, S; Ming, WK; Wang, H; Weng, X | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Balcueva, E; Barlow, WE; Conlin, AK; Dy, PA; Gralow, JR; Hayes, DF; Hicks, JB; Hortobagyi, GN; Kuhn, P; Lew, DL; Moore, HCF; Pusztai, L; Schott, AF; Somlo, G; Tripathy, D; Welter, L; Yeon, CH | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Acconcia, F | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gersch, CL; Gralow, JR; Hayes, DF; Henderson, NC; Henry, NL; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Medley, S; Mehta, RS; Pusztai, L; Rae, JM; Rutherford, DV; Tirumali, NR; Vandenberg, TA | 1 |
35 review(s) available for fulvestrant and anastrozole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen | 2022 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles | 2001 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
Fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Survival Rate; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2003 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Immunohistochemistry; Injections, Intramuscular; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2005 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles; Women | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Complementary Therapies; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Remission Induction; Treatment Outcome | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
34 trial(s) available for fulvestrant and anastrozole
| Article | Year |
|---|---|
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; North America; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2002 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Treatment Outcome; Triazoles | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Survival Analysis; Survival Rate; Triazoles | 2005 |
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2009 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2011 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Recurrence; Triazoles | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2012 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Neoplasm Staging; Nitriles; Treatment Outcome; Triazoles | 2012 |
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Grading; Nitriles; Postmenopause; Preoperative Care; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2015 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Estradiol; Female; Fulvestrant; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Hypoglycemic Agents; Maximum Tolerated Dose; Middle Aged; Nitriles; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
Topics: Anastrozole; Breast Neoplasms; Drug Interactions; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Female; Follow-Up Studies; France; Fulvestrant; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Triazoles | 2016 |
Endogenous Estrogen Regulates Somatostatin-Induced Rebound GH Secretion in Postmenopausal Women.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Double-Blind Method; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Human Growth Hormone; Humans; Middle Aged; Nitriles; Postmenopause; Somatostatin; Triazoles | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2016 |
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; China; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Taiwan; Triazoles | 2018 |
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Quality of Life; Surveys and Questionnaires | 2018 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Goserelin; Humans; Neoplasm Metastasis; Premenopause; Tamoxifen | 2018 |
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA, Neoplasm; Female; Fulvestrant; Gene Expression Profiling; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Postmenopause; Prognosis; RNA, Neoplasm; Th1 Cells | 2018 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival | 2019 |
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2019 |
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Fulvestrant; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis | 2020 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
46 other study(ies) available for fulvestrant and anastrozole
| Article | Year |
|---|---|
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cells, Cultured; Choriocarcinoma; DNA Primers; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblasts; Fulvestrant; Humans; Letrozole; Microsomes; Nitriles; Placenta; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 1998 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Chorionic Gonadotropin, beta Subunit, Human; Dehydroepiandrosterone; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Nitriles; Triazoles; Tumor Cells, Cultured | 2000 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Arteriosclerosis; Cell Adhesion; Dihydrotestosterone; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation; Humans; Male; Mice; Nitriles; Receptors, Estrogen; RNA, Messenger; Testosterone; Triazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2002 |
New alternative to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2002 |
Concept evaluation: an assay for receptor-mediated and biochemical antiestrogens using pubertal rats.
Topics: Administration, Oral; Anastrozole; Animals; Biological Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Injections, Subcutaneous; Nitriles; Oligopeptides; Organ Size; Rats; Rats, Wistar; Sexual Maturation; Tetrahydronaphthalenes; Triazoles; Uterus; Vagina | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Spreading the word, but not too thinly.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Editorial Policies; Estradiol; Female; Fulvestrant; Humans; Nitriles; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Treatment Outcome; Triazoles | 2004 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Current and future perspectives on fulvestrant.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Triazoles | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Lung Neoplasms; Nitriles; Progestins; Triazoles | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Estradiol; Female; Fulvestrant; Humans; Mice; Mice, Nude; Nitriles; Organ Size; Ovariectomy; Receptors, Growth Factor; Signal Transduction; Triazoles; Tumor Burden; Tumor Cells, Cultured; Uterus; Xenograft Model Antitumor Assays | 2008 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Effects of 17beta-estradiol on rat urinary bladder: gender differences in anoxia-glucopenia and reperfusion damage.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Glucose; Hypoxia; In Vitro Techniques; Injections, Subcutaneous; Male; Muscle Contraction; Neuroprotective Agents; Nitriles; Rats; Rats, Wistar; Reperfusion Injury; Sex Factors; Testosterone; Time Factors; Triazoles; Urinary Bladder; Urinary Bladder Diseases | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
In vivo treatments with fulvestrant and anastrozole differentially affect gene expression in the rat efferent ductules.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Ejaculatory Ducts; Estradiol; Fulvestrant; Gene Expression Regulation; Male; Nitriles; Rats; Rats, Wistar; Sp1 Transcription Factor; Testosterone; Transcription Factor AP-1; Triazoles | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Models, Biological; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Triazoles | 2011 |
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2012 |
Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol.
Topics: 5-alpha Reductase Inhibitors; Anastrozole; Androgen Antagonists; Animals; Aorta; Aromatase Inhibitors; Cell Adhesion; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Estradiol; Estrogen Antagonists; Female; Finasteride; Flutamide; Fulvestrant; Monocytes; Myocytes, Smooth Muscle; Nitric Oxide; Nitriles; Rats; Rats, Wistar; Testosterone; Triazoles | 2012 |
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Carcinogens; Cell Proliferation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nicotiana; Nitriles; Nitrosamines; Receptors, Estrogen; Triazoles | 2012 |
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Prognosis; Triazoles | 2012 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2013 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles | 2014 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Estradiol; Female; Fulvestrant; Humans; Markov Chains; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2017 |
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.
Topics: Anastrozole; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Echocardiography; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hemodynamics; Humans; Hypertension, Pulmonary; Insulin Resistance; Lung; Mice; Mice, Knockout; Mutation; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Fulvestrant; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2018 |
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Practice Guidelines as Topic; Treatment Outcome | 2018 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Fulvestrant enables better outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fulvestrant; Humans | 2019 |
First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Follow-Up Studies; Fulvestrant; Humans; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cinnamates; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; Mammary Neoplasms, Experimental; Mice, Nude; Postmenopause; Selective Estrogen Receptor Modulators | 2020 |
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Fulvestrant; Health Care Costs; Humans; Markov Chains; Quality-Adjusted Life Years | 2020 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Effects of
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Estradiol; Female; Fulvestrant; Genotype; Humans; Nitriles; Triazoles | 2023 |